It is intriguing to speculate that not only in these conditions but also for different patient groups affected by systemic hypoxemia (e.g., acute respiratory distress syndrome, chronic obstructive pulmonary disease or COVID-19), increasing Hb–O2 affinity (e.g., with 5-HMF administration) may be a beneficial intervention. The gene discussed is GSTM1; the disease is COVID-19.